OasisLMS

Episode 7: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host Dr. Masahiro Torasawa, the corresponding author of "Tumor Inflammation–Associated Neurotoxicity Masquerading as Severe Immune Effector Cell–Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report" published in the Journal of Thoracic Oncology July issue. 

Also featured in this episode is the article "TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors" by Di Federico et al.

Articles Discussed:

• Tumor Inflammation–Associated Neurotoxicity Masquerading as Severe Immune Effector Cell–Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report
• TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors
• July 2026 Issue

Podcast Hosts:

• Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
• Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Podcast Guest:

• Masahiro Torasawa, MD, PhD, Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan